ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,090.27
      0.25%
      US Tech 100
      21,034.92
      0.78%
      Dow Jones
      44,642.52
      -0.28%
      Brent Oil
      70.95
      0.00%
      Bitcoin
      99,595.71
      -0.33%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Windtree Therapeutics Inc (WINT)

      7. Windtree Therapeutics Inc (WINT) News

      Windtree Therapeutics Inc

      Windtree Therapeutics Inc (WINT)

      NASDAQ
      0.37
      -0.0182
      (-4.69%)
      Closed December 06 4:00PM
      Delayed by 15 minutes
      0.3651
      -0.0049
      (-1.32%)
      After Hours: 7:53PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      WINT News

      Official News Only

      Form 8-K - Current report
      Edgar (US Regulatory)
      December 05 2024
      WINT (-4.69%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      December 04 2024
      WINT (-4.69%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 27 2024
      WINT (-4.69%)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
      Edgar (US Regulatory)
      November 14 2024
      WINT (-4.69%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 14 2024
      WINT (-4.69%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      October 09 2024
      WINT (-4.69%)

      WINT Discussion

      View Posts
      Monksdream Monksdream 3 weeks ago
      WINT, new 52 low
      👍️0
      Monksdream Monksdream 4 weeks ago
      WINT 10Q due 11/11
      👍️0
      Mr. Zen Mr. Zen 1 month ago
      Took another position here, this could very easily be a $30.00 stock in 2 years, patience pays.
      👍️0
      tw0122 tw0122 1 month ago
      Ping pong .80s to $1s
      👍️0
      Mr. Zen Mr. Zen 2 months ago
      This may be the bottom for a longer term play,if they are successful with phase three it will be a $30.00 +/- stock. IMO
      👍 1
      glenn1919 glenn1919 2 months ago
      WINT.....................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
      👍️0
      tw0122 tw0122 2 months ago
      WINT take smaller gain .94s to $1.20 exit having trouble on bigger breakout to $1.40s
      👍️0
      tw0122 tw0122 2 months ago
      1.11 test again
      👍️0
      tw0122 tw0122 2 months ago
      WINT $1.11 breakout solid and $1.44
      Up next 3m floater
      👍️0
      Mr. Zen Mr. Zen 2 months ago
      Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.
      👍️0
      Monksdream Monksdream 2 months ago
      WINT new 52 week low
      👍️0
      Monksdream Monksdream 2 months ago
      WINT new 52=week low
      👍️0
      Roadtojourney Roadtojourney 2 months ago
      Yup they pr only to dilute there share pos?? Imo
      👍️0
      Mr. Zen Mr. Zen 2 months ago
      Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the trial design of its SEISMiC Phase 2b has been published by the European Society of Cardiology Heart Failure. The article is entitled, “Safety and efficacy of up to 60 hours of intravenous istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.” It can be found online in Wiley Online Library DIO: 10.1002/ehf2.15102. Results can be viewed at https://ir.windtreetx.com/corporate-presentation. The Heart Failure Society of America also shared the results.
      👍️0
      tw0122 tw0122 2 months ago
      $1.26 + 36%
      👍️0
      tw0122 tw0122 2 months ago
      Pump it
      👍️0
      Monksdream Monksdream 2 months ago
      WINT anew 52 week low
      👍️0
      Monksdream Monksdream 2 months ago
      WINT under $2
      👍️0
      Mr. Zen Mr. Zen 2 months ago
      Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
      👍️0
      Monksdream Monksdream 2 months ago
      WINT new 52 week low
      👍️0
      Awl416 Awl416 2 months ago

      On September 25, 2024, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Company’s Phase 2b SEISMiC Extension Study of istaroxime in treating early cardiogenic shock due to heart failure. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
      👍️0
      glenn1919 glenn1919 3 months ago
      WINT...................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783
      👍️0
      na na na na 3 months ago
      There's a big borrowing fee. 50 dollars in losses per 1000 dollars of shorted shares per day.
      👍️0
      tw0122 tw0122 3 months ago
      FOR RESALE OF UP TO 27.7 MILLION SHARES BY THE SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: Further company coverage:

      Wow!!
      👍️0
      tw0122 tw0122 3 months ago
      My bad 10 million shares offering announced recently this won’t go anywhere. Share selling machine short it
      👍️0
      tw0122 tw0122 3 months ago
      Pop it to $5 already another 400k floater $3.85 resistance watch
      👍️0
      Awl416 Awl416 3 months ago
      Don’t blink
      👍️0
      na na na na 3 months ago
      If you short 1000 dollars of shares you're now paying 70 dollars a day in fees,Up from 50 dollars of fees a few days ago.




      👍️0
      na na na na 3 months ago
      Jumped from 700 percent to 800 percent borrow fee.

      👍️0
      Anite Anite 3 months ago
      For the upcoming trading day on Friday, 6th we expect Windtree Therapeutics Inc to open at $3.05 and during the day (based on 14 day Average True Range), to move between $3.10 and $4.75, which gives a possible trading interval (+/-54.61%) up from last closing price. If Windtree Therapeutics Inc takes out the full calculated possible swing range there will be an estimated 109.21% move between the lowest and the highest trading price during the day.
      👍️0
      Anite Anite 3 months ago
      Last week:First, the private placement delivers needed capital to support company operations, including the active Phase 2b clinical trial for istaroxime in cardiogenic shock. Second, the transaction fully converted and eliminated senior notes, including senior secured notes we used as bridge financing over the past several months eliminating this debt from our balance sheet.” 
      Windtree shares are blasting higher on heavy volume Friday with more than 9 million shares
      👍️0
      Anite Anite 3 months ago
      Borrow rates now 1500%!!!!!
      🚀 1
      Mr. Zen Mr. Zen 3 months ago
      Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability of istaroxime to improve heart function and low blood pressure in the setting of early cardiogenic shock due to heart failure. The Company is looking to extend the positive results on these parameters as observed in the Company’s first SEISMiC Phase 2 clinical study that was previously reported. In addition, the Company hopes that the study results will substantiate the encouraging observations from the Company’s Phase 2 clinical study, indicating istaroxime has a favorable renal profile and does not increase cardiac arrhythmias. The SEISMiC Extension Study is utilizing longer dosing duration and tapering the dosing to assess the potential benefits.

      Istaroxime is a novel first-in-class therapy that has demonstrated the ability to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function in patients with compromised cardiac function in three positive Phase 2 trials enrolling patients with acute heart failure (AHF). Cardiogenic shock is a serious condition that can occur when AHF patients continue to deteriorate and the heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. Mortality rates are significant and, depending on severity, range from 7% to 40% in the U.S. There is a lack of satisfactory pharmacological intervention to reverse the condition as available therapies have unwanted side effects such as risk for arrhythmias, decreased blood pressure, and renal dysfunction that limit their usefulness and position them as “rescue medicines” for severe cases. The cardiogenic shock worldwide total market value is estimated to be $1.25 billion per year.
      👍️0
      na na na na 3 months ago
      RIP SHORTS! 50 dollars per 1000 dollars of share fee.
      👍️0
      na na na na 3 months ago
      👍️0
      Awl416 Awl416 3 months ago
      Oh cmon
      👍️0
      na na na na 3 months ago
      SQUEEZE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

      700 percent borrowing rate!!!


      If you short 1000 dollars of stock you pay a fee of 52 dollars a day!

      🚀 1
      willlbone willlbone 3 months ago
      Get up and go, got up and WINT.
      👍️0
      na na na na 3 months ago
      Buy the dip!!

      👍️0
      TIMGZ TIMGZ 4 months ago
      WHAAAAT**** LARGEST SHORT INTEREST****44%
      👍️0
      Monksdream Monksdream 4 months ago
      WINT 10Q due AUGUST 20
      👍️0
      Awl416 Awl416 4 months ago
      Watch out
      👍️0
      Awl416 Awl416 4 months ago
      Quite the close
      👍️0
      Monksdream Monksdream 4 months ago
      WINT under $9
      👍️0
      Zardiw Zardiw 4 months ago
      $WINT +200% #DDAmanda Video Analysis - #1 Stock Scanner/Screener



      Z
      👍️0
      PaladinOcean33 PaladinOcean33 4 months ago
      WINT 4.40s
      👍️0
      Mr. Zen Mr. Zen 4 months ago
      That is what phase three trials are all about, do not expect much for another 6 to 9 months. Then it is either break out or bust, dig into it a bit.
      👍️0
      Luckysevens Luckysevens 4 months ago
      “They just have to prove it” yeah thats the problem lolz
      👍️0
      peterus peterus 4 months ago
      relax bro i will do some dd
      👍️0
      Mr. Zen Mr. Zen 4 months ago
      no do some research here,they have a product that works they just have to prove it. Its call [phase three results, God I am so tired of these mouthy kids on this site
      👍️0

      Your Recent History

      NASDAQ
      WINT
      Windtree Therapeutics
      Delayed Upgrade Clock